 |
|
VCU Massey Cancer Center Spearheads Novel Clinical Study for Lymphoma Patients
September 03, 2008The Virginia Commonwealth University Massey Cancer Center recently opened a National Cancer Institute (NCI)-sponsored, phase II clinical study for certain sub-types of non-Hodgkin's lymphoma.
The study is based on research from VCU Massey Cancer Center as well as other centers suggesting that combining two novel, recently approved drugs that have shown effectiveness in certain blood cancers may be active in patients with diffuse large B-cell lymphoma, or mantle cell lymphoma. The study is intended for patients whose disease has progressed following treatment with other regimens.
Other NCI centers participating in this novel lymphoma study through the NCI's Southeast Phase II Consortium include H. Lee Moffitt Cancer Center and Research Institute (Tampa, Fla.), which is the coordinating center; the University of North Carolina Lineberger Comprehensive Cancer Center (Chapel Hill, N.C.); and the Vanderbilt-Ingram Cancer Center (Nashville, Tenn.). Also planning to participate are Montefiore-Einstein Cancer Center (New York); and New York Presbyterian Hospital / Weill Cornell Medical College, both of which are in the NCI-sponsored New York Phase II Consortium.
The investigators hope to learn whether these types of lymphoma respond to treatment with the combination of bortezomib, marketed as Velcade, and vorinostat, marketed as Zolinza. They also intend to learn about the side effects of this drug regimen and whether certain features of these lymphomas might predict for response to this regimen.
Steven Grant, M.D., principal investigator of the study and associate director for translational research at VCU Massey Cancer Center, is among a number of researchers worldwide who have reported synergistic interactions between proteasome inhibitors such as bortezomib and histone deacetylase inhibitors such as vorinostat in leukemia and other hematologic malignancies. Other cancer centers are currently exploring this drug combination in patients with refractory multiple myeloma.
"Phase I data from studies in patients with multiple myeloma have given us a good idea of safe and appropriate doses of these two agents when they are administered in combination. Such information has allowed us to open this as a Phase II study in patients with lymphoma to determine how effective this novel drug combination is in this setting," said Grant. "The hematologic cancer research community has considerable interest in combination regimens incorporating these two important classes of new agents."
Within the mantle cell lymphoma patient group, the study will assess whether patients who have previously received bortezomib respond differently from those who have never been treated with bortezomib. Bortezomib administered alone has recently been approved for the treatment of patients with relapsed or refractory mantle cell lymphoma, and previously was approved for patients with progressive multiple myeloma. Vorinostat has been approved for use in patients with cutaneous T-cell lymphoma.
Diffuse large B-cell lymphoma is a type of non-Hodgkin's lymphoma - cancer of the immune system - that is usually fast-growing. It is the most common type of non-Hodgkin's lymphoma, and is characterized by rapidly growing tumors in the lymph nodes, spleen, liver, bone marrow or other organs. Other symptoms include fever, night sweats and weight loss. There are several subtypes of diffuse large B-cell lymphoma.
Mantle cell lymphoma is a fast-growing type of B-cell non-Hodgkin's lymphoma that usually occurs in middle-aged or older adults. It is marked by small- to medium-size cancer cells that may be in the lymph nodes, spleen, bone marrow, blood, and gastrointestinal system.
The VCU Massey Cancer Center
The investigators hope to learn whether these types of lymphoma respond to treatment with the combination of bortezomib, marketed as Velcade, and vorinostat, marketed as Zolinza. They also intend to learn about the side effects of this drug regimen and whether certain features of these lymphomas might predict for response to this regimen.
Steven Grant, M.D., principal investigator of the study and associate director for translational research at VCU Massey Cancer Center, is among a number of researchers worldwide who have reported synergistic interactions between proteasome inhibitors such as bortezomib and histone deacetylase inhibitors such as vorinostat in leukemia and other hematologic malignancies. Other cancer centers are currently exploring this drug combination in patients with refractory multiple myeloma.
"Phase I data from studies in patients with multiple myeloma have given us a good idea of safe and appropriate doses of these two agents when they are administered in combination. Such information has allowed us to open this as a Phase II study in patients with lymphoma to determine how effective this novel drug combination is in this setting," said Grant. "The hematologic cancer research community has considerable interest in combination regimens incorporating these two important classes of new agents."
Within the mantle cell lymphoma patient group, the study will assess whether patients who have previously received bortezomib respond differently from those who have never been treated with bortezomib. Bortezomib administered alone has recently been approved for the treatment of patients with relapsed or refractory mantle cell lymphoma, and previously was approved for patients with progressive multiple myeloma. Vorinostat has been approved for use in patients with cutaneous T-cell lymphoma.
Diffuse large B-cell lymphoma is a type of non-Hodgkin's lymphoma - cancer of the immune system - that is usually fast-growing. It is the most common type of non-Hodgkin's lymphoma, and is characterized by rapidly growing tumors in the lymph nodes, spleen, liver, bone marrow or other organs. Other symptoms include fever, night sweats and weight loss. There are several subtypes of diffuse large B-cell lymphoma.
Mantle cell lymphoma is a fast-growing type of B-cell non-Hodgkin's lymphoma that usually occurs in middle-aged or older adults. It is marked by small- to medium-size cancer cells that may be in the lymph nodes, spleen, bone marrow, blood, and gastrointestinal system.
The VCU Massey Cancer Center
Lymphoma Current Events and Lymphoma News RSSResearchers aim to over-stress already taxed mantle cell lymphoma cells
Cancer cells are already stressed by the fast pace they require to grow and spread and scientists believe a little more stress just may kill them.
UC Davis researchers discover Achilles' heel in pancreatic cancer
UC Davis Cancer Center researchers have discovered a metabolic deficiency in pancreatic cancer cells that can be used to slow the progress of the deadliest of all cancers.
Chronic inflammation can help nurture skin cancer, study shows
Inflammation, a frontline defense against infection or disease, can help nurture skin cancer, researchers have found.
Hodgkin lymphoma -- new characteristics discovered
Researchers are still discovering new characteristics of Hodgkin lymphoma, a common form of cancer of the lymphatic system. The malignant cells are derived from white blood cells (B cells), but have lost a considerable part of the B cell-specific gene expression pattern.
How to differentiate abdominal tuberculosis from lymphomas?
The incidence of tuberculosis is increasing. Lymphadenopathy is the most common manifestation of abdominal tuberculosis and may, in up to 55% of cases without other evidence of abdominal involvement, be easily confused with lymphomas involving abdominal lymph nodes.
NC State Is First University in Nation to Offer Canine Bone Marrow Transplants
Dogs suffering from lymphoma will be able to receive the same type of medical treatment as their human counterparts, as North Carolina State University becomes the first university in the nation to offer canine bone marrow transplants in a clinical setting.
Researchers discover how rheumatoid arthritis causes bone loss
Researchers have discovered key details of how rheumatoid arthritis (RA) destroys bone, according to a study published in the Aug. 22 edition of the Journal of Biological Chemistry.
Duke chemists synthesize promising anti-cancer product
Duke University chemists have patented an efficient technique for synthesizing a marine algae extract in sufficient quantities to now test its ability to inhibit the growth of cancerous cells while leaving normal cells unaffected.
Children's national co-leads nationwide study of landmark sickle cell treatment
Children's National Medical Center immunologist and blood and marrow transplant physician Naynesh Kamani, MD, will serve as the study co-chair for a new national clinical trial of unrelated donor marrow and umbilical cord blood transplants for severe sickle cell disease.
Rheb's role in cancer
Two independent papers in the August 15th issue of G&D identify the Rheb GTPase as a novel oncogene and a promising new chemotherapeutic target.
More Lymphoma Current Events and Lymphoma News Articles
 | Living with Lymphoma: A Patient's Guide by Elizabeth M. Adler "Adler's professional background and experience as a lymphoma survivor make her the perfect person to write this book. The author's explanations are a gentle guide and a thorough introduction to the basics that give us the confidence to handle decisions relating to treatments and other aspects of lymphoma." -- Anne Atkinson, non-Hodgkin lymphoma and Hodgkin disease survivor and coordinator of the... |
 | An Illustrated Guide to Skin Lymphoma by Lorenzo Cerroni, Kevin Gatter, Helmut Kerl Skin lymphomas are relatively rare. They may arise in the skin itself and as a by-product of HIV infection, or may arise elsewhere as a result of Hodgkin's disease, B cell lymphomas or leukaemia. Whatever the cause, they can easily be overlooked as psoriasis or dermatitis. Diagnosis of skin lymphoma is difficult and making the wrong diagnosis can prove fatal. Consequently, those in... |
 | 100 Questions & Answers About Lymphoma by Peter Holman, Jodi Garrett, William D. Jansen This book deals with lymphoma from a doctor's and a caregiver's... |
| UNDERSTANDING NON-HODGKIN'S LYMPHOMA A GUIDE FOR PATIENTS by LYMPHOMA RESEARCH-FOUNDATION | |
 | Lymphoma: Pathology, Diagnosis and Treatment Major advances have occurred in almost every aspect of the diagnosis and treatment of lymphoma in recent years. Our understanding of the molecular biology and genetics of the disease has increased exponentially, and significant developments in imaging of this malignancy have resulted in earlier and more accurate diagnosis. At the same time, advances in therapeutic immunology have led to the... |
 | Lymphoma (Fast Facts) by Chris Hatton, Graham Collins, John, M.D. Sweetenham Lymphomas arise from a single abnormal lymphocyte, yet many different subtypes of lymphoma occur. Recent advances in cellular and molecular techniques have revolutionized physicians' understanding of this malignancy, and there have been dramatic developments in diagnosis and treatment. "Fast Facts: Lymphoma" gives a comprehensive and up-to-date perspective on this challenging disease written by... |
 | Non-Hodgkin's Lymphomas: A Self-Study Program Harvard Medical School, Boston, MA. Provides information on the biology, diagnosis, staging, and treatment of all forms of non-Hodgkin's lymphomas, reflecting a multidisciplinary approach. Each disease includes coverage on the clinical evaluation and selection of treatment. Abundant color illustrations. For physicians and residents. DNLM: Lymphomas,... |
 | Extranodal Lymphomas: Pathology and Management |
 | Malignant Lymphomas (Atlas of Clinical Oncology.) by Michael L. Grossbard MD Malignant Lymphomas is a volume in the acclaimed American Cancer Society Atlas of Clinical Oncology series. Dr. Grossbard and his team have summarized current knowledge on the pathology, epidemiology, molecular biology, presentation and management of patients with both non-Hodgkin's lymphoma and Hodgkin's disease. The experts address the disease group by type - indolent B-cell lymphoma,... |
 | Non-Hodgkin's Lymphomas: Making Sense of Diagnosis, Treatment and Options by Lorraine Johnston Prior to publication of this resource guide, no book on the market targeted the non-Hodgkin's lymphoma survivor's need for understandable information. While there are medical texts on the non-Hodgkin's lymphomas as well as inspirational first-person accounts from survivors of related cancers such as leukemia, between these two sources of information existed a considerable information gap. In... |
| © 2008 BrightSurf.com |